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Abstract Breast cancers related to BRCA mutations are
associated with particular biological features. Here we
report the clinical and pathological characteristics of breast
cancer in Chinese women with and without BRCA muta-
tions and of carriers of BRCA1 mutations compared to
BRCA2 mutations. Two hundred and 26 high-risk Hong
Kong Chinese women were tested for BRCA mutations,
medical information was obtained from medical records,
and risk and demographic information was obtained from
personal interviews. In this cohort, 28 (12.4%) women
were BRCA mutation carriers and among these carriers,
39.3% were BRCA1 and 60.7% were BRCA2 mutations.
Mutation carriers were more likely to have a familial his-
tory of breast and ovarian cancer, high-grade cancers, and
triple negative (TN) cancers. Prevalence of TN was 48.3%
in BRCA carriers and 25.6% in non-carriers and was 67.7%
in BRCA1 and 35.3% in BRCA2 carriers. Estrogen receptor
(ER) negative cancer was significantly associated withPreliminary results presented in part at San Antonio Breast Cancer
Symposium 10–14 December 2008 and ASCO meeting 29 May—2
June 2009.
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BRCA1 mutations, especially in those under 40 years of
age. BRCA-related breast cancer in this Chinese population
is associated with family history and adverse pathological/
prognostic features, with BRCA2 mutations being more
prevalent but BRCA1 carriers having more aggressive and
TN cancers. Compared to Caucasian populations, preva-
lence of BRCA2 mutations and TN cancer in BRCA2
mutation carriers in Chinese population are elevated.
Keywords Breast cancer  BRCA mutation  Pathology 
Clinical features  Chinese
Abbreviations
DCIS Ductal carcinoma in situ
TN Triple negative cancer
LVI Lymphovascular invasive
ER Estrogen receptor
PR Progesterone receptor
Introduction
BRCA mutations are known to be related to breast cancers
with distinct clinical and pathological features compared to
sporadic breast cancers (Basu et al. 2008; Atchley et al.
2008). There are also known clinical and pathologic dif-
ferences between tumors arising from inheritance of
mutations of BRCA1 and BRCA2 genes (Chappuis et al.
2000). In addition, studies in Western literature report
potential epidemiological, clinical, and biological differ-
ences in breast cancer between Asian and Caucasian pop-
ulations (John et al. 2007, Fackenthal and Olopade 2007).
These data highlight the need to determine clinical and
pathological characteristics in BRCA carriers in different
populations, since these differences may affect future risk
assessment, treatment planning, and outcomes.
To address these issues we report information from a
multicenter study of Chinese high-risk patients residing in
the Hong Kong Special Administrative Region of the
People’s Republic of China (HKSAR) in Southern China.
This study identifies clinical and tumor pathologic features
of breast cancer related to BRCA mutation inheritance,
compared to those without mutations, and compares can-
cers from BRCA1 and BRCA2 mutation carriers.
Materials and method
Patients
A total of 226 clinically high-risk breast and/or ovarian
cancer patients (probands), referred to the Hong Kong
Hereditary and High Risk Breast Cancer Programme (
www.HRBCP.org) from March 2007 to November 2008,
were recruited prospectively. Based on the lower incidence
of breast cancer in Asia cohorts, clinically high risk female
patients who were included in this study; were defined as
those who: (1) had at least one-first- or second- degree
relative with breast and/or ovarian cancer, regardless of
age; (2) were less than 50 years of age at diagnosis; (3) had
bilateral breast cancer; (4) had triple negative (TN) or
medullary type pathology; (5) had at least one relative with
cancers other than breast and ovarian cancer that are known
to be related to BRCA mutations; or (6) they were an
ovarian cancer patient with a family history of breast
cancer. A standard epidemiological questionnaire, includ-
ing a detailed family history, was administered to patients
and medical information, including pathology reports, was
retrieved from the patient’s medical records. Information
from the epidemiological questionnaire included age at
breast cancer diagnosis, other cancers diagnosed in the
patient, and a family history of breast, ovarian, and other
cancers in first, second, and third degree relatives. In
addition, the following were categorized as having been
used or not used: alcohol; tobacco; contraceptive pills,
patches or injections; hormone replacement treatments; and
infertility medications. Women were also asked if they had
ever been pregnant and breast fed any child and if they
were pre- or post-menopausal. Eligible patients were
offered BRCA counseling and testing, and were consented
for genetic testing and blood and tumor collection. Patients
who tested positive for a BRCA mutation were asked to
help recruit their first-degree relatives, who were also
offered testing. This project was approved by the Ethical
Committees of all the participating hospitals and centers in
Hong Kong.
BRCA mutation detection by conventional DNA
sequencing and MLPA
BRCA1 and BRCA2 mutation detection was performed on
genomic DNA extracted from peripheral blood samples or
paraffin embedded tissues, as described previously (Kwong
et al. 2008). Mutation analysis was performed by direct
DNA sequencing of all coding exons of BRCA1 and
BRCA2 and multiplex ligation-dependent probe amplifi-
cation (MLPA) (Sellner and Taylor 2004; Hogervorst et al.
2003; Schouten et al. 2002, Bunyan et al. 2004).
Clinical and pathological assessment
Clinical and pathological features included in the analysis
were abstracted from medical records. These factors,
related to extent of cancer at diagnosis and to treatment
and prognosis, include: (a) type of breast cancer (in situ or
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invasive); (b) grade (1–3, with lower numbers indicating
more normal looking and slower growing cancers); stage
(measure of extent of disease using the TNM system); (c)
tumor size (T0, no tumor or in situ, sometimes classified as
Tis, T1 = \ 2 cm, T2 = 2–5 cm, T3 = [ 5 cm); (d)
lymph nodes (N) (N0 = no spread to nodes, N1 = 1–3
nodes, N2 = 4–9 nodes, N3 = [ 9 nodes plus other cri-
teria); (e) metastasis to distant organs (M0 = no spread,
M1 = spread to other organs); (f) lymphatic invasion
(LVI), which is usually detected from tumor on prepared
slides; (g) Ki67, an index (%) measuring a cancer antigen
found in dividing cells; and (h) three receptors related to
tumor cells accepting or rejecting estrogen (ER), proges-
terone (PR), or HER2/neu, all of which tend to fuel growth
of breast cancer and are determinants of treatment and
prognosis. The final measure is ‘‘triple negative’’ cancer,
which are tumors that are ER-, PR-, and HER2-. The ER/
PR scoring is performed by the Allred scoring system in
which comprised of proportion score and intensity score.
The proportional score (i.e. % of positive cells) is: 0,
completely negative; 1, \1/100; 2, 1/100–1/10; 3, 1/10–1/
3; 4; 1/3–2/3 and 5, [2/3. The intensity score is: 0, nega-
tive; 1, weak; 2, intermediate and 3, strong. The total score
is the sum of both and a score of[2 is considered positive.
The HER2 criterion is based on ASCO/CAP guideline
2007. HER2 positive is defined as IHC3? and if 2? will
reflex to FISH and categorized as HER2? for a ratio of
[2.2 (HER2 to chromosome 17 ratio) on dual colour
system. A HER2 negative result is defined as IHC 0 or 1?
(Allred et al. 1998).
Statistical analysis
Chi Square (X2) test was used to determine differences in
characteristics among mutation carriers and non-carriers
and between BRCA1 and BRCA2 carriers, with P-value of
0.05 or less being statistically significant, when data were
categorical (Fisher’s Exact test was used where counts
were less than five). Linear by linear associations were
used when data were ordinal. A case–control analytic
approach was used to estimate the odds ratios of demo-
graphic, behavioral, clinical, and pathological variables
being associated with carrier status and, if a carrier, being a
BRCA1 or a BRCA2 carrier. Odds ratios (OR) and 95%
confidence intervals (CI) were estimated using logistic
regression models (SPSS 16.0, SPSS Inc, Chicago, USA).
Univariate (unadjusted) models were used since multivar-
iate analyses were limited by small sample sizes. However,
where multivariate models were possible the OR’s were
similar to the univariate models.
Results
Risk factors
A total of 226 female patients who met the criteria for
being at high risk for breast cancer were tested for BRCA
mutations and 28 (12.4%) were mutation carriers, of which
11 (39.3%) were BRCA1 and 17 (60.7%) were BRCA2
mutations. Fifty (22.1%) of these women had bilateral
breast cancer; 32.1% among BRCA carriers and 20.7%
among non-carriers. The median age at diagnosis of breast
cancer was 42 years (range 21–82). Seven patients also
had ovarian cancer and their median age at ovarian cancer
diagnosis was 49 years (range 23–65). All patients were
Chinese of which 84% originated from Guangdong prov-
ince of Southern China. The majority (69.3%) was born in
Hong Kong but over 70% of their parents were born in
Mainland China.
When all patients was categorized into those less than
age 40 and 40 or above, 55.6% of BRCA mutation carriers
had breast cancer diagnosed before 40 years of age, com-
pared to 36.0% of non-carriers, which is statistically sig-
nificant at P = 0.05 and has an OR of 0.45; CI, 0.20–1.02
(Table 1). Our data also shows that BRCA carriers were 10
times more likely to have also been diagnosed with ovarian
cancer (4/28; 14.3%) than non-carriers (3/198; 1.5%) (OR,
10.83; CI, 2.29, 51.34; P = 0.005). Only one ovarian
cancer was seen in patients less than 40 years of age and
she was in a mutation carrier. BRCA carriers and non-
carriers did not differ for any of the other risk factors
shown in Table 1 (use of alcohol, tobacco, contraceptive
pills, infertility drugs, and hormone replacement therapy,
having breast fed; and being menopausal); Although there
is no statistically significance, mutation carriers were twice
as likely to those who never have been pregnant as non-
carriers (OR, 0.50; CI, 0.23–1.12.; P = 0.09).
Family history and age
BRCA mutation carriers were three times more likely to
report family history of any cancer than non-carriers (OR,
3.05; CI 0.88–10.51) but this did not reach a significant
difference (Table 2). BRCA carriers were statistically more
likely to have relatives with breast cancer (OR, 2.99; CI,
1.29–6.93; P = 0.01) and ovarian cancer in family mem-
bers (OR, 5.13; CI, 1.70–15.47; P = 0.002), compared to
non-carriers. Furthermore, there was also statistically sig-
nificant in linear relationship between the number of family
members with breast cancer for BRCA carriers and non
carriers, when looking at any family member (1st, 2nd, and
3rd degree relatives) with breast cancer (OR(1 vs. 3
?
), 25.6;
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CI, 4.88–134.37) or only considering 1st degree relatives
(OR(1 vs. 2
?
), 25.00; CI, 2.87–218.18). No statistical differ-
ence was seen for 2nd degree relatives. Twenty-two of the
women with breast cancer were from families with both
breast and ovarian cancer; 32% of BRCA carriers and 7%
of non-carriers (data not shown). Of those with a family
history of other malignancies, the most common were lung,
colon, liver, nasopharyngeal, gastric, esophageal, and
pancreatic cancers (data not shown), but there were no
statistical difference between carriers and non-carriers.
Mutation carriers were more likely to have family members
with breast cancer when stratified by age (Table 3). This
association was seen in both age groups, but was only
statistically different when the age group was over 40 (OR,
3.75; CI, 1.01–14.51; P = 0.04). The opposite was true for
a family history of ovarian cancer where carriers age 40 or
Table 1 Association of breast cancer risk factors between BRCA mutation carriers and non-carriers (N = 226)
BRCA Mutations
Carriers (N = 28)* Non-carriers (N = 198)* Unadjusted
n Col % n Col % v2 P-value OR 95% CI
Age first diagnosed with breast cancera
Age group:
\40 15 55.6 71 36.0 1.00**
C40 12 44.4 126 64.0 3.82 0.05 0.45 (0.20, 1.02)
Had ovarian cancer
No 24 85.7 195 98.5 1.00
Yes 4 14.3 3 1.5 13.33 0.005 10.83 (2.29, 51.34)
Alcohol:
No 27 96.4 182 91.9 1.00**
Yes 1 3.6 16 8.1 0.72 0.40 0.42 (0.05, 3.31)
Smoking:
No 26 92.9 184 92.9 1.00**
Yes 2 7.1 14 7.1 \0.001 0.99 1.01 (0.22, 4.70)
Taking contraceptive pills/injection/patch:
No 17 63.0 107 56.9 1.00**
Yes 10 37.0 81 43.1 0.35 0.55 0.78 (0.34, 1.79)
Taking hormonal replacement treatment:
No 16 84.2 108 90.0 1.00**
Yes 3 15.8 12 10.0 0.57 0.45 1.69 (0.43, 6.64)
Taking infertility drug:
No 25 100.0 175 96.2
Yes 0 0.0 7 3.8 0.99 1.00 – –
Whether had breast feed a child:
No 14 77.8 90 66.7 1.00**
Yes 4 22.2 45 33.3 0.90 0.34 0.57 (0.18, 1.84)
Menopause:
No 14 50.0 103 52.0 1.00**
Yes 14 50.0 95 48.0 0.04 0.84 1.08 (0.49, 2.39)
Ever been pregnant:
No 13 46.4 60 30.3 1.00**
Yes 15 53.6 138 69.7 2.92 0.09 0.50 (0.23, 1.12)
Bold figure: Significant at \0.05
a There were two patients with ovarian cancer only, so there were 224 patients with breast cancer
* Values may not sum to 100% because of missing data
** Referent
 Univariate Odd Ratios comparing ‘‘Carriers’’ versus ‘‘Non-carriers’’ (reference group)
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younger were nine times more likely to have relatives with
ovarian cancer (OR, 8.63; CI, 1.30–57.17; P = 0.04),
compared to non-carriers (Table 3). Although younger age
increases mutation carrier rate (OR, 0.45 (\40 vs. C 40); CI,
0.20–1.02; P = 0.05). The presence of family history
increases the chance of BRCA mutation by 2–10 times.
Without family history, women age 41 and above have a
low risk of mutation (0–8.3%) in this cohort (Table 6).
Cancer types
Fifty of the 226 women had bilateral breast cancer; 32.1%
(9/28) of BRCA mutation carriers and 20.7% (41/198) of
non-carriers. There were 22 synchronous and 28 metach-
ronous cancers and although BRCA mutation carriers had a
higher percentage of metachronous cancers (88.9%, 8/9 vs.
48.8%, 20/41), the difference was not statistically
significant (P = 0.06). Both carriers and non-carriers who
were younger than age 40 were significantly more likely to
have metachronous cancer than the older group (87.5%, 14/
16 vs. 41.2%, 14/34; P = 0.002). The opposite was true for
those with age above 40 were synchronous cancer is more
likely (12.5%, 2/16 vs. 58.8%, 20/34; P = 0.002) (data not
shown). Without family history chance of a women with
bilateral breast cancer to carry a BRCA mutation is 10%
but this doubles in the presence of family history (Table 6).
The distribution of all 276 cancers found in the 226
patients (50 had bilateral cancer) according to patholog-
ical characteristics is shown in Table 4. BRCA carriers
had higher grade cancers (Grade 3) than non-carriers
(OR(grade 1–2 vs. 3), 2.56; CI, 1.06–6.19; P = 0.03), but
less lymphatic invasion (LVI) of cancer cells (OR, 0.18;
CI, 0.04–0.80; P = 0.01). BRCA carriers were less likely
to have invasive cancer when compared to in situ cancer,
Table 2 Association of BRCA mutation carriers and non-carriers and family history of breast and ovarian cancers
BRCA Mutations
Carriers (N = 28)* Non-carriers (N = 198)* Unadjusted
n Col % n Col % v2 P-value OR 95% CI
Family history
Whether family members had any cancer:
No 3 10.7 53 26.8 1.00**
Yes 25 89.3 145 73.2 3.39 0.07 3.05 (0.88, 10.51)
Type of cancer for family members
Breast cancer:
No 9 32.1 116 58.6 1.00**
Yes 19 67.9 82 41.4 6.94 0.01 2.99 (1.29, 6.93)
Ovarian cancer:
No 22 78.6 188 94.9 1.00**
Yes 6 21.4 10 5.1 10.00 0.002 5.13 (1.70, 15.47)
Breast cancer (among families with breast cancer, n = 101)
No. of family member had breast cancer:
1 5 26.3 64 78.0 1.00**
2 8 42.1 15 18.3 0.003 6.83 (1.95, 23.85)
C3 6 31.6 3 3.7 22.47 <0.001 25.60 (4.88, 134.4)
No. of 1st degree relative had breast cancer:
0 1 5.3 25 30.5 1.00**
1 7 36.8 46 56.1 0.22 3.80 (0.44, 32.70)
C2 11 57.9 11 14.4 19.25 0.004 25.00 (2.87, 218.2)
No. of 2nd degree relative had breast cancer:
0 12 63.2 58 70.7 1.00**
1 5 26.3 20 24.4 0.75 1.21 (0.38, 3.86)
2 2 10.5 4 4.9 0.76 0.34 2.42 (0.40, 14.73)
Bold figure: significant at \0.05
* Values may not sum to 100% because of missing data
** Referent
 Univariate Odd Ratios comparing ‘‘Carriers’’ versus ‘‘Non-carriers’’ (reference group)
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but this was not statistically significant (OR, 0.58; CI,
0.24–1.40; P = 0.22). Within invasive cancer compari-
son, BRCA carriers were significantly more likely to have
smaller cancers (OR(T1 vs. T2–4),0.41; CI, 0.17–0.98;
P = 0.05). No differences were seen between carriers and
non-carriers for stage cancers (OR(stage 1 vs. stages 2–4),
0.63; CI, 0.26–1.52; P = 0.3), cancers with less lymph
node involvement (OR(N1 vs. N1-3), 0.57; CI, 0.23–1.39;
P = 0.21). metastatic spread. BRCA mutation carriers
were also more likely to have cancers being negative for
ER (OR, 2.78; CI, 1.28–5.88), PR (OR, 2.44; CI, 1.10–
5.56), and HER2 (OR, 2.13; CI, 0.93, 5.00), and two
times more likely to have TN cancer (OR, 2.11, CI, 1.22–
5.88) than non-carriers (Table 4). Even without family
history, 11.1% of those with TN cancers are BRCA
mutation carriers although presence of family history
doubles this risk (29.3%). In the presence of family
history, TN patients are still more likely to be a mutation
carrier (OR 2.65; CI 1.12–6.29; P = 0.024).There was no
difference in Ki-67 expression between the two groups.
Comparison of BRCA1and BRCA2 Cancers
As shown in Table 5, breast cancers patients with BRCA1
mutations were compared to patients with BRCA2 muta-
tions. Of the 37 cancers found in the 28 BRCA carriers (9
had bilateral cancer), 15 (41%) were BRCA1 carriers and
22 (59%) were BRCA2 carriers. BRCA1 carriers were
younger at diagnosis than BRCA2 carriers; 80.0% vs.
41.2% were less than 40 years of age (data not shown).
BRCA1 carriers had more invasive cancers (92.3% vs.
66.7%), but this is not statistically different (OR, 6.00; CI,
0.65–50.00). In excluding Stage 0 cancers to compare only
invasive cancers, BRCA1 carriers were more likely to have
large tumors (OR (T1 vs. 2), 7.69; CI, 1.16–5.00; P = 0.04)
although cancers in BRCA1 carriers were no different when
compared to BRCA2 carriers by stage (OR (stage 1 vs. 2?),
1.17, CI, 0.22–6.08; P = 0.12).. There were too few cases
with nodal involvement to calculate an OR using N1 as the
referent.
Examining biomarkers, BRCA1 mutation related cancers
are significantly more likely to be ER negative, 75.0% vs.
36.8% (OR, 5.14; CI, 1.03–25.60; P = 0.04), but there
were no statistical differences in either PR or HER2 tumors
between the two groups. The prevalence of TN cancers in
BRCA1 carriers was 67.7% vs. 35.3% in BRCA2 carriers,
although this was not statistically significant (OR, 3.67; CI
0.77–17.43) (Table 5). Furthermore, BRCA2 and BRCA1
carriers did not have significant differences in the number
of family members with breast cancer or ovarian cancer in
these families (data not shown).
Outcome
Though not shown in any of the tables, there was no sig-
nificant difference in the type of surgery (breast conser-
vation and mastectomy) received between BRCA mutation
carriers and non-carriers (P = 0.31). The median follow-
Table 3 Association between BRCA mutation carriers and non-carriers for personal and family history of breast and ovarian cancer by age
BRCA mutations v2 P-value Unadjusted
Carriers (N = 28)* Non-Carriers (N = 198)*
n Col % n Col % OR 95% CI
Family history
Whether family members had breast cancer:
\40 No 6 40.0 46 64.8 1.00**
Yes 9 60.0 25 35.2 3.18 0.07 2.76 (0.88, 8.65)
C40 No 3 25.0 70 55.6 1.00**
Yes 9 75.0 56 44.4 4.11 0.04 3.75 (1.01, 14.51)
Whether family members had ovarian cancer:
\40 No 12 80.0 69 97.2 1.00**
Yes 3 20.0 2 2.8 6.68 0.04 8.63 (1.30, 57.17)
C40 No 10 83.3 118 93.7 1.00**
Yes 2 16.7 8 6.3 1.74 0.21 2.95 (0.55, 15.81)
Bold figure: significant at \0.05
* Values may not sum to 100% because of missing data
** Referent
 Univariate Odd Ratios comparing ‘‘Carriers’’ versus ‘‘Non-carriers’’ (reference group)
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Table 4 Association between BRCA mutation carriers and breast cancer pathology
BRCA mutations
Carriers (N = 28) * Non-Carriers (N = 239) * Unadjusted
n Col % n Col % v2 P-value OR 95% CI
LVI (Lymphatic invasion):
Absent/suspiciousa 20 90.9 107 64.5 1.00**
Present 2 9.9 59 35.5 6.20 0.01 0.18 (0.04, 0.80)
Grade:
1 and 2 9 37.5 103 60.6 1.00**
3 15 62.5 67 39.4 4.59 0.03 2.56 (1.06, 6.19)
Type:
DCIS (Ductal carcinoma In Situ) 8 23.5 33 15.2 1.00**
Invasive 26 76.5 84 84.8 1.49 0.22 0.58 (0.24, 1.40)
Stage:
Stage 0 8 25.8 32 15.7
Stage 1 10 32.3 56 27.5 1.00**
Stage 2, 3, and 4 13 41.9 116 56.9 1.80 0.30 0.63 (0.26, 1.52)
T stage (Tumor size):
T0 8 24.2 30 14.6
T1 16 48.5 74 36.1 1.00**
T2, 3 and 4 9 27.3 84 41.0 6.50 0.05 0.41 (0.17, 0.98)
N stage (Lymph node involvement):
N0 22 75.9 130 64.0 1.00**
N1, 2, and 3 7 24.1 73 36.0 1.57 0.21 0.57 (0.23, 1.39)
M stage (Metastatic):
M0 32 100.0 201 95.7
M1 0 0 9 4.3 1.42 0.23 – –
ER (Estrogen receptor):
Positive 15 48.4 141 72.3 1.00**
Negative 16 51.6 54 27.7 7.16 0.007 2.78 (1.28, 5.88)
PR (Progesterone receptor):
Positive 11 36.7 112 58.6 1.00**
Negative 19 63.3 79 41.4 5.07 0.02 2.44 (1.10, 5.56)
Cerb 2 (Protein of HER2 Oncogene):
Positive 9 31.0 87 49.2 1.00**
Negative 20 69.0 90 50.8 3.29 0.07 2.13 (0.93,5.00)
Triple negative (ER-/PR-/Cerb2-):
No 15 51.7 131 74.4 1.00**
Yes 14 48.3 45 25.6 6.26 0.01 2.11 (1.22, 5.88)
Ki67 index (% of growing cells):
\12% 6 60.0 28 50.9 1.00**
[12% 4 40.0 27 49.1 0.28 0.60 0.69 (0.18,2.70)
a There were two BRCA non-carriers and two BRCA carriers with LVI suspicious
Bold figure: Significant at \0.05
* Values may not sum to 100% because of missing data
** Referent
 Includes 41 bilateral cancers in non-mutation carriers (14%) and 9 bilateral cancers in mutation carriers (24%)
 Univariate Odd Ratios comparing ‘‘Carriers’’ versus ‘‘Non-carriers’’ (reference group)
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Table 5 Association between BRCA1 and BRCA2 mutation carriers and breast cancer pathology
BRCA Mutations
BRCA1 (n = 15) BRCA2 (n = 22) Unadjusted
n Col % n Col % v2 P-value OR 95% CI
LVI (Lymphatic invasion):
Absent/suspiciousa 9 90.0 11 91.7 1.00**
Present 1 10.0 1 8.3 0.02 0.89 1.22 (0.07, 20.00)
Grade:
2 4 36.4 5 38.5 1.00**
3 7 63.6 8 61.5 0.01 0.92 1.10 (0.17,4.81)
Type:
DCIS (Ductal carcinoma In Situ) 1 7.7 7 33.3 1.00**
Invasive 12 92.3 14 66.7 2.93 0.09 6.00 (0.65, 50.00)
Stage:
Stage 0 1 8.3 7 36.8
Stage 1 5 41.7 5 26.3 1.00**
Stage 2, 3 6 50.0 7 36.8 1.28 0.86 1.17 (0.22, 6.08)
T stage (Tumor size):
T0 1 7.7 7 35.0
T1 5 38.5 11 55.0 1.00**
T2 7 53.8 2 10.0 7.52 0.04 7.69 (1.16, 5.00)
N stage (Lymph node involvement)
N0 11 91.7 11 64.7 1.00**
N1 and 2 1 8.3 6 35.3 2.89 0.12 0.17 (0.02,1.61)
ER (Estrogen receptor):
Positive 3 25.0 12 63.2 1.00**
Negative 9 75.0 7 36.8 4.29 0.04 5.14 (1.03, 25.60)
PR (Progesterone receptor):
Positive 3 25.0 8 44.4 1.00**
Negative 9 75.0 10 55.6 1.17 0.28 2.40 (0.48, 11.93)
Cerb 2 (Protein of HER2 Oncogene):
Positive 4 33.3 5 29.4 1.00**
Negative 8 66.7 12 70.6 0.05 0.82 0.83 (0.17, 4.09)
Triple negative (ER-/PR-/Cerb2-):
No 4 33.3 11 64.7 1.00**
Yes 8 67.7 6 35.3 2.77 0.10 3.67 (0.77, 17.43)
Ki67 index (% of growing cells):
\12% 1 100.0 5 55.6
[12% 0 0.0 4 44.4 0.74 0.39 – –
a There were only two BRCA2 with LVI suspicious
Bold figure: P-value \0.05
* Values may not sum to 100% because of missing data
** Referent
 Includes 4 bilateral cancers in BRCA1 mutation carriers (27%) and 5 bilateral cancers in BRCA2 mutation carriers (23%)
 Univariate Odd Ratios comparing ‘‘Carriers’’ versus ‘‘Non-carriers’’ (reference group)
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Table 6 Association between BRCA mutation carriers and breast cancer pathology
BRCA mutations
Non-carriers (n = 198)* Carriers (n = 28)* Unadjusted
n Row % n Row % v2 P-value OR 95% CI
Age first diagnosed to have breast cancer
Age group:
B40
Without FH 22 91.7 2 8.3 1.00**
With FH 52 78.8 14 21.2 2.00 0.22 2.96 (0.62, 14.14)
Without bilateral cancer 63 85.1 11 14.9 1.00**
With bilateral cancer 11 68.8 5 31.2 2.42 0.15 2.60 (0.76, 8.96)
Non TN 46 83.6 9 16.4 1.00**
TN 17 63.0 10 37.0 4.35 0.037 3.01 (1.04, 8.67)
41–45
Without FH 12 100.0 0 0.0 1.00**
With FH 38 92.7 3 7.3 0.93 1.00 – –
Without bilateral cancer 42 97.7 1 2.3 1.00**
With bilateral cancer 8 80.0 2 20.0 4.75 0.088 # 10.50 (0.85, 130.07)
Non TN 33 97.1 1 2.9 1.00**
TN 10 83.3 2 16.7 2.74 0.16 6.60 (0.54, 80.61)
46–50
Without FH 11 91.7 1 8.3 1.00**
With FH 27 87.1 4 12.9 0.18 1.00 1.63 (0.16, 16.27)
Without bilateral cancer 29 90.6 3 9.4 1.00**
With bilateral cancer 9 81.8 2 18.2 0.62 0.59 2.15 (0.31, 14.94)
Non TN 23 85.2 4 14.8 1.00**
TN 10 100.0 0 0.0 1.66 0.56 – –
[50
Without FH 8 100.0 0 0.0 1.00**
With FH 27 90.0 3 10.0 0.87 1.00 – –
Without bilateral cancer 22 88.0 3 12.0 1.00**
With bilateral cancer 13 100.0 0 0.0 1.69 0.54 – –
Non TN 29 96.7 1 3.3 1.00**
TN 8 80.0 2 20.0 3.00 0.15 7.25 (0.58, 90.55)
Without bilateral cancer
Without FH 44 95.7 2 4.3 1.00**
With FH 113 86.9 17 13.1 2.69 0.16 3.31 (0.73, 14.92)
With bilateral cancer
Without FH 9 90.0 1 10.0 1.00**
With FH 32 80.0 8 20.0 0.54 0.67 2.25 (0.25, 20.44)
Non triple negative (ER-/PR-/Cerb2-):
Without FH 35 100.0 0 0.0 1.00**
With FH 96 86.5 15 13.5 5.27 0.022 – –
Had triple negative (ER-/PR-/Cerb2-):
Without FH 16 88.9 2 11.1 1.00**
With FH 29 70.7 12 29.3 2.28 0.19 1.26 (0.97, 1.62)
No FH and non TN 35 100.0 0 0.0
No FH and TN 16 88.9 2 11.1
FH and non TN 96 86.5 15 13.5
FH and TN 29 70.7 12 29.3 13.66 0.003 – –
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up time for the cohort was 19 months for both carriers and
non-carriers. BRCA mutation carriers, however, may have
more local relapse or second primary cancer compared to
non-carriers (15.6% vs 7.5%, P = 0.13), but the mean time
to local relapse showed no significant difference between
BRCA mutation carriers and non-carriers. Only three BRCA
mutation carriers had relapse at the time of analysis.
Discussion
Most studies of BRCA gene mutations have been conducted
in Western populations. Limited studies have been carried
out in Chinese populations but none have described the
clinico-pathological characteristics in detail. Women in our
study were referrals to the Hong Kong Hereditary and High
Risk Breast Cancer Programme and they were selected for
testing for BRCA mutations using similar criteria as other
studies, except women with breast cancer under 50 years of
age were accepted even if they did not have any family
history of cancer and if they had even one other family
member with breast or ovarian cancer irrespective of age.
These inclusion criteria are less stringent than other studies,
which would suggest that the expected BRCA mutation rate
may be lower than measured in other studies. In contrast,
the detection rate of 12.4% was slightly higher than that
reported in other Chinese series (Song et al. 2005; Chen
et al. 2008; Suter et al. 2004; Ng et al. 2008; Li et al. 1999;
Song et al. 2006; Sng et al. 2000). This high prevalence of
BRCA mutations may be due to a genuinely higher rate of
BRCA mutations in our cohort or to the nature of the
referrals to our clinic compared to others.
In our cohort, women with BRCA mutations were more
likely to be diagnosed with breast cancer at less than
40 years of age compared to non-carriers and in our sub-
group analysis BRCA1 mutation carriers were younger than
BRCA2 carriers, as seen in the western literature. Although
the overall mean age at diagnosis of breast cancer is
younger than Caucasians in our locality, this finding may
be due to the small sample size and a larger population is
needed to confirm this difference although the overall mean
age at diagnosis of breast cancer is younger in Hong Kong
than some other populations.
Patients with BRCA mutations more commonly have a
personal and family history of breast and/or ovarian cancer
than non-carriers. Amongst mutation carriers, the number
of family members with breast cancer (67.9%) and with
ovarian cancer (21.4%) is high which is similar to that seen
in the Western literature (Frank et al. 2002) but higher than
in a previous study in mainland China, which looked at
only BRCA1 mutations where 40% had family members
with breast or ovarian cancers (Li et al. 2006). It has also
been reported that carriers of BRCA1 mutations have a
greater family history of ovarian cancers than BRCA2
mutation carriers (Gayther et al. 1999, Ramus et al. 2007).
However, unlike Caucasian data the distribution of family
members with breast and ovarian cancer is similar for the
BRCA1 and BRCA2 groups in our cohort. This may be
attributed to the higher BRCA2 mutation carriage generally
in our cohort.
Apart from the increased risk of breast and ovarian
cancer, increased risk of a broad spectrum of cancers in the
Western literature has been reported in mutation carriers.
In particular, these included stomach (Brose et al. 2002;
Johannsson et al. 1999), pancreas (Lynch et al. 2005),
prostate (Moslehi et al. 2000) and colon cancer (Breast
Cancer Information Core (BIC) Database). In our cohort
we found a similar spectrum of cancers although these
cancers did not have a significant increase in frequency,
which may be due to the small number of carriers in our
cohort. There is a comparatively high percentage of
stomach, colon and pancreas cancers in families of patients
Table 6 continued
BRCA mutations
Non-carriers (n = 198)* Carriers (n = 28)* Unadjusted
n Row % n Row % v2 P-value OR 95% CI
With family history
Non TN 96 86.5 15 13.5 1.00**
TN 29 70.7 12 29.3 5.09 0.024 2.65 (1.12, 6.29)
Bold figure: P-value \0.05; # mean marginally significant
* Values may not sum to 100% because of missing data
** Referent
 Includes 41 bilateral cancers in non-mutation carriers (14%) and 9 bilateral cancers in mutation carriers (24%)
 Univariate Odd Ratios comparing ‘‘Carriers’’ versus ‘‘Non-carriers’’ (reference group)
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with BRCA mutations (Kirchhoff et al. 2004; Tiling et al.
2001; Niell et al. 2004; Jakubowska et al. 2002). Although
it is likely that the phenotypic presentation of other cancers
is related to the BRCA mutations, since some of these
family members with other cancers have not been tested for
mutations we cannot rule out the occurrence of sporadic
cancers in these families. One family with a novel BRCA2
mutation showed stomach cancer only in one generation
and breast cancer in the next generation, with a BRCA2
mutation found in both members with breast and stomach
cancer, thus illustrating the relationship between BRCA2
mutation and stomach cancer (Kwong et al. 2008).
It has been observed that the risk of secondary cancer in
women who have a family history of breast cancer is
increased and, therefore, likely to be genetically related
(Bernstein et al. 1992; Anderson and Badzioch 1985).
Unselected cases of bilateral breast cancer are also related
to BRCA mutations although the relationship is not strong,
ranging from 5% to 20% where early onset bilateral breast
cancer increases such association. Contralateral breast
cancer has been reported to increase in women with
hereditary breast cancer (Robson et al. 1999; Lucassen
et al. 2001). In our cohort only 50 patients had bilateral
breast cancer and the mutation rate was 18% (9/50),
comparable to 5–20% found in Western literature (Imy-
anitov and Hanson 2003). Women with metachronous
tumors tended to be younger at diagnosis as compared with
those having synchronous bilateral cancers in our cohort,
which is similar to that reported (Gogas et al. 1993;
Hartman et al. 2005).Family history, however, still plays an
important role in this group of patients where the mutation
rate doubles in the presence of family history.
The mutation rate of women with DCIS in our study were
found to be high (19.5%, 8/41) compared to Western studies
(range 0.8–12.7%) (Smith et al. 2007; Claus et al. 2005). The
knowledge of the association between BRCA mutation and
DCIS is still relatively limited but there is increasing data
suggesting that this association is comparable to that of
invasive cancers particularly when it is due to an early onset
breast cancer (Hwang et al. 2007; Smith et al. 2007). In our
study among carriers the percent with DCIS was 23.5% and
among non-carriers the percent was 15.2%.
Several studies have suggested that there are biologic
differences between women who carry germline BRCA
mutations to that of non-carriers. Specifically, there have
been various reports which found tumors related to such
mutation to be of higher grade (Eisinger et al. 1996; Joh-
annsson et al. 1997; Atchley et al. 2008). In our study,
BRCA related cancers compared to those which are were
2.56 times more likely to be grade 3 compared to grades 1
and 2, whereas there is no significant difference in grades
when BRCA1 and BRCA2 related cancers were compared,
both having higher grade cancers overall.
In our cohort of patients BRCA carriers were more likely
to have TN cancers (48.3%) compared to non-carriers
(25.6%), and this TN rate in mutation carriers is similar to
that found in recent studies in Caucasian populations (53%)
(Haffty et al. 2006). Though not statistically significant the
prevalence of TN cancers is much higher in BRCA1 car-
riers (66.7%) compared to BRCA2 carriers (35.3%), similar
to that have been reported previously (Schneider et al.
2008); although amongst BRCA2 mutation carriers our
cohort had a higher TN rate compared to the West (14%)
and it is reversed in BRCA 1(80%) (Haffty et al. 2006).
Even without family history, the BRCA mutation rate is
still 11.1% suggesting that it is worthwhile to perform
genetic testing even in this sporadic group. Presence of
family history double of presence of a BRCA mutation.
The BRCA1 associated tumors are five times more likely to
be ER negative as compared to BRCA2 mutation carriers
(P = 0.04), similar to that described in Western and Asian
literatures (Noguchi et al. 1999; Larson et al. 1999, Joh-
annsson et al. 1997). These findings are consistent with
more recent findings from the Western literatures sug-
gesting that BRCA1 associated tumors have distinct imm-
unnohistopathological profiles based on gene expression
profile, that they are more likely to have basal-like tumor
phenotype (Fatouros et al. 2008; Fine et al. 2003; Silva
et al. 2008; Johannsson et al. 1997; van der Groep et al.
2006), and are usually that of higher grade, and have higher
mitotic count (Lakhani et al. 1998) apart from its associ-
ation with triple negativity. BRCA2 related breast cancers,
compared the BRCA1 cancers are less likely to behave like
basal-like cancers and are more heterogeneous.
Whether BRCA mutation carriers are more likely to have
local recurrence than non carriers is still inconclusive.
Some studies suggest that local recurrence rates are com-
parable between the two groups (Lucassen et al. 2001)
although in contrast some other studies found a higher rate
of ipsilateral breast cancer recurrence (Lucassen et al.
2001; Moran et al. 2008, Seynaeve et al. 2004). In our
study there is a trend for more local relapse in BRCA
mutation carries and that the time to local relapse is shorter.
However, due to the relatively short follow-up time and
also a limitation in sample size, a larger study sample
would be necessary for making such conclusions. The
published literature suggests a superior outcome in those
breast cancer which are hereditary related (Albano et al.
1982; Porter et al. 1994) although some other studies
suggested worse prognosis for BRCA mutation carriers
(Moran et al. 2008; Petit et al. 2005; Foulkes et al. 2000;
Ansquer et al. 1998) or at least comparable outcomes
(Verhoog et al. 1999).
This study has some limitations, the primary one being
the small sample size, although it is much larger than many
other reports. We are continuing to recruit women to this
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study and will be able to obtain more stability in finding as
the cohort grows in size. These findings are from women
with breast cancer who were referred to a high risk breast
cancer clinic and who were selected for this analysis based
on very specific criteria related to the probability of being a
BRCA carrier, but most studied to date have used high risk
clinics to recruit women for these studies. But this work
does preclude any generalization to the population preva-
lence of these cancers and their characteristics. We are now
recruiting general cancer cases from all of the major hos-
pitals in Hong Kong which will allow us to draw conclu-
sions in the future from women who more generally
represent the Hong Kong population. Finally, although
follow-up was not a major part of this study, this cohort
needs to be followed much longer to study the recurrence
rates, the incidence of additional cancers, and the survival
rates as they are related to these personal, genetic, clinical
and molecular characteristics of these women.
In conclusion, in this study of 226 Chinese women who
had 276 breast cancers that were seen at our high risk clinic
we identified a very high BRCA2 mutation rate in our
cohort. The higher prevalence of BRCA2 mutations in our
cohort, compared to Western cohorts, will allow further
studies on this group of carriers. In our study, BRCA related
breast cancer is associated with increasing number of first-
degree relatives with breast and/or ovarian cancers and
with higher rates of DCIS cancers. Prevalence of TN breast
cancers in BRCA 2 mutation carriers was high compared to
Caucasian cohorts and TN significantly increases BRCA
mutation rate even in the presence of no family history.
Pathologically, specific poor prognostic features are asso-
ciated with BRCA mutation especially in the younger age
group. This however, may not translate into a worse clin-
ical outcome in this group of patients and longer follow up
and further studies are necessary to understand the outcome
of this group of high-risk patients. BRCA1 related cancers,
though having a lower prevalence that BRCA2 cancers,
were generally more aggressive cancers with immunno-
histopathological profiles showing that these cancers are
more related to the triple negative phenotype.
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